Nnomo Assene Aristine, Dieme Denis, Jomaa Malek, Côté Jonathan, Bouchard Michèle
Department of Environmental and Occupational Health, Chair in Toxicological Risk Assessment and Management, and Public Health Research Center (CReSP), University of Montreal, Roger-Gaudry Building, U436, P.O. Box 6128, Main Station, Montreal, Quebec H3C 3J7, Canada.
Department of Environmental and Occupational Health, Chair in Toxicological Risk Assessment and Management, and Public Health Research Center (CReSP), University of Montreal, Roger-Gaudry Building, U436, P.O. Box 6128, Main Station, Montreal, Quebec H3C 3J7, Canada.
Toxicol Lett. 2024 Feb;392:56-63. doi: 10.1016/j.toxlet.2024.01.006. Epub 2024 Jan 11.
Canada has recently invested in the large-scale exploitation of scandium oxide. However, there are no studies available to date to understand its toxicokinetics in the animal or human body, which is necessary to assess exposure and health risks. The aim of this research was to investigate the toxicokinetics of absorbed scandium oxide (ScO) using the rat as an experimental model. Male Sprague-Dawley rats were injected intravenously with 0.3 or 1 mg ScO/kg body weight (bw). Blood and excreta (urine and feces) were collected sequentially during a 21-day period, and main organs (liver, spleen, lungs, kidneys, brain) were withdrawn at sacrifice on day 21. Inductively coupled plasma-mass spectrometry (ICP-MS) was used for the measurement of Sc element in the different samples. The mean residence time (MRT) calculated from the blood profile was 19.7 ± 5.9 h and 43.4 ± 24.6 h at the lower and higher doses, respectively. Highest tissue levels of Sc were found in the lungs and liver; respective lung values of 10.6 ± 6.2% and 3.4 ± 2.3% of the Sc dose were observed at the time of sacrifice while liver levels represented 8.9 ± 6.4% and 4.6 ± 1.1%. Elimination of Sc from the body was not complete after 21 days. Cumulative fecal excretion over the 21-day collection period represented 12.3 ± 1.3% and 5.9 ± 1.0% of the lower and higher Sc doses, respectively, and showed a significant effect of the dose on the excretion; only a small fraction of the Sc dose was recovered in urine (0.025 ± 0.016% and 0.011 ± 0.004% in total, respectively). In addition to an effect of the dose on the toxicokinetics, results highlight the importance of the lung as a site of accumulation and retention of ScO, which raises the question of the risks of effects related to respiratory exposure in workers. The results also question the relevance of urine as a matrix for biological exposure monitoring. A more in-depth inhalation toxicokinetic study would be necessary.
加拿大最近已投资大规模开采氧化钪。然而，迄今为止尚无研究来了解其在动物或人体中的毒代动力学情况，而这对于评估暴露情况和健康风险是必要的。本研究的目的是使用大鼠作为实验模型来研究吸收的氧化钪（ScO）的毒代动力学。给雄性斯普拉格 - 道利大鼠静脉注射0.3或1毫克ScO/千克体重（bw）。在21天的时间段内依次收集血液和排泄物（尿液和粪便），并在第21天处死时取出主要器官（肝脏、脾脏、肺、肾脏、大脑）。使用电感耦合等离子体质谱法（ICP-MS）测量不同样品中的Sc元素。根据血液曲线计算出的平均驻留时间（MRT）在较低剂量和较高剂量时分别为19.7±5.9小时和43.4±24.6小时。Sc在肺和肝脏中的组织水平最高；在处死时，肺中Sc剂量的相应值分别为10.6±6.2%和3.4±2.3%，而肝脏水平分别为8.9±6.4%和4.6±1.1%。21天后，Sc从体内的消除并不完全。在21天的收集期内，累积粪便排泄量分别占较低和较高Sc剂量的12.3±1.3%和5.9±1.0%，并且显示出剂量对排泄有显著影响；在尿液中仅回收了一小部分Sc剂量（分别总计为0.025±0.016%和0.011±0.004%）。除了剂量对毒代动力学的影响外，结果突出了肺作为ScO积累和滞留部位的重要性，这引发了关于工人呼吸道暴露相关影响风险的问题。结果还对尿液作为生物暴露监测基质的相关性提出了质疑。有必要进行更深入的吸入毒代动力学研究。
